Background
death
Covid-19 was a leading direct and indirect cause of death worldwide during the first years of the pandemic [The Immunomodulation-CoV Assessment (ImmCoVA) multicenter study was initiated during the first wave of covid-19 in Sweden. At the time there were no published randomized controlled trials of any covid-19 therapies, but some non-randomized retrospective studies suggested a possible benefit using tocilizumab and anakinra [